Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Medical World News

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

Asthma

Atopic Dermatitis

Biosimilars

Breast Cancer

COPD

COVID-19

Cholangiocarcinoma

Chronic Kidney Disease

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Digital Health

Employers

Epilepsy

Heart Failure

Hematology

Hemophilia

Immuno-Oncology

Infectious Disease

Inflammation

Leukemia and Lymphoma

Liver

Lung Cancer

Lupus

Major Depressive Disorder

Medicare

Multiple Myeloma

Myasthenia Gravis

Myelodysplastic Syndromes

Oncology

Ophthalmology

Parkinson Disease

Prostate Cancer

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Rare Disease

Reimbursement

Respiratory

Rheumatology

Skin Cancer

Sleep

Spinal Muscular Atrophy

Type 1 Diabetes

Vaccines

Women's Health

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

eNewsletter

Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.

She has a BA in print journalism from Penn State University. You can connect with Jaime on 

Articles

This analysis found that the 3000 patients with hemophilia had higher rates of pain, depression, and anxiety medication use.

Use of Pain, Depression, Anxiety Meds Higher Among Patients With Hemophilia

Former NBA star Magic Johnson has partnered with GSK to educate the public about this virus, specifically in seniors and those at high-risk for contracting a severe form of RSV.

 Raising Awareness About RSV in Older Adults

Mary is the associate editorial director for The American Journal of Managed Care® (AJMC®), The Center for Biosimilars®, and Evidence-Based Oncology™. She joined AJMC® in 2013 and oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®.

She has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on 

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

Delivery Matters: In Early Studies, DPX Technology Allows  Vaccines to Persist When Cancer Pushes Back 

Between 2019 and 2020, there were 97 reported shortages among sponsor-reported antiseizure medications in Australia, 93% of which were generic brands.

Shortages of Antiseizure Meds Continue, More Common Among Generics: Australian Report

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

1rem

Compendium

 Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

 enter different markets around the globe, payers and practices will need to consistently evaluate the economics of covering biosimilars and take a stance on whether to support their adoption.

Both payers and practices can play a big role in encouraging biosimilar adoption, and health care institutions that have already begun pushing for more biosimilar use, such as Emory Healthcare, have seen substantial savings.

On this episode of Managed Care Cast, we speak with Ryan Haumschild, PharmD, MS, MBA, the director of pharmacy services at Emory Healthcare and the Winship Cancer Institute. Haumschild is also an Advisory Board member for The American Journal of Managed Care® and its sister site, 

®. The interview took place at the The Institute of Value-Based Medicine® (IVBM), hosted by Emory Healthcare, on July 18 in Atlanta, Georgia. Haumschild was chair of the event and gave a presentation on the current pharmacoeconomics of biosimilars and his predictions for how the market will develop in the future.

The episode discussed how the pharmacoeconomics of biosimilars have evolved and different strategies that health care institutions can implement to reap the benefits of biosimilar savings.

We also talked about how stakeholders can collaborate to promote biosimilars and how technology can be used to assist this mission.

Listen to the interview above or through one of these podcast services:

On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

, we like to show you what scientists, researchers, health care providers, and others are doing in their spare time to relax and recharge. On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and a member of the advisory board of 

, a sister site to AJMC.com, the website of 

, he spoke with Matthew Gavidia, an associate editor at AJMC.com, about his unusual whiskey-making hobby, the history of the traditional process, and how he distills his own biosimilar version.


Listen to an excerpt of the interview above or through one of these podcast services:

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

What’s ahead for hospitals and health systems in projected drug spending for 2022?

, which looks at what purchasers can expect next year. The report, which delves into its members’ purchasing patterns, predicts a 3.1% increase in pharmaceutical spending next year, with oncology drugs accounting for about 25% of the increase. The report also discusses increasing competition from 

, including the recent approval of insulin glargine as an interchangeable biosimilar for the treatment of 

; the practice of white bagging; and other issues. 

On this episode of Managed Care Cast, we speak with Steven Lucio, PharmD, BCPS, senior principal, Pharmacy Solutions, about the report, which also discusses the continued impact of COVID-19 on health care.

Listen above or through one of these podcast services:

Vizient recently released its Summer 2021 Pharmacy Market Outlook, which projects pharmaceutical spending for 2022 based on an analysis of its members' data. On this episode of Managed Care Cast, we talk about some of the findings.

 Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient

Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA. In this episode of Managed Care Cast, Kelly Davio, senior editor of The Center for Biosimilars

, discusses new approvals; what the loss of Scott Gottlieb, MD, as FDA commissioner means; the reality of pay-for-delay deals; and more.

Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States. 

Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA.

Biosimilars Are Being Approved but Not Reaching the Market

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place in 2018. Kelly Davio, senior editor of 

, highlights recent progress, how the US market compares with Europe, and what remains to be seen.

You may need to log in to the website to access this podcast.

Stakeholders Weigh In on the Key Biosimilar Developments of 2018

Coherus Confirms That It Has Launched Its Pegfilgrastim Biosimilar, Udenyca

Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen

Pfizer Becomes Latest to Settle With AbbVie Over Humira

Read more about the stories in this podcast:

Last year was a big year for biosimilars in the United States, with the number of FDA-approved biosimilars nearly doubling and major policy and regulatory developments taking place.

Progress in the US With Biosimilars, but Opportunities Remain

 recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.

Trump Administration Gives States More Power to Alter ACA Exchange Offerings

CMS Reports Data Breach in ACA Agent and Broker Portal

CMS Cuts Budget for ACA Marketing to $10 Million for 2019 Plan Year

Payments Are Increasingly Tied to Value, but More Risk-Based Models Needed

Drug Market to See More Competition, Launch of Biosimilars in 2019

The Academy of Managed Care Pharmacy Nexus 2018

Dr Barbara McAneny Discusses the Effect of OCM's Second Performance Period Results

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Podcast: This Week in Managed Care&mdash;States Gain Power to Alter ACA Offerings and Other Health News

This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs.

Healthcare Mergers Continue With Deal for Cigna to Acquire Express Scripts

What We're Reading: Verma on Health Data; More Medicaid Work Requirements; NJ Individual Mandate

Azar Tells Insurance Industry Patients Must Be in Charge of Their Own Data

FDA's Gottlieb Blames Rebates, Reimbursement Issues for Holding Back Biosimilar Market

What We're Reading: Azar to Announce Healthcare Actions; Opposition to CMS Opioid Limits; Diabetes Disagreement

Expedited Approval Is Successful for Cancer Therapies, FDA Says

The Shift From Episodic to Continuous Care: Wearable Technology and Telemedicine in Cardiology

American College of Cardiology’s 67th Annual Scientific Session & Expo